基线维生素D水平对替诺福韦治疗慢性乙型肝炎疗效的影响

肝脏 ›› 2021, Vol. 26 ›› Issue (6): 621-624.

基线维生素D水平对替诺福韦治疗慢性乙型肝炎疗效的影响

李轩, 张丽娜, 王松, 王方, 聂广, 何清

518100 广东深圳市第三人民医院肝病医学中心

收稿日期:2020-11-10 出版日期:2021-06-30 发布日期:2021-07-19
通讯作者: 何清,Email:heqingjoe@163.com
基金资助:
深圳市科技计划项目(SZFZ2017064),深圳市医学重点学科建设经费资助(SZXK076)

The association of baseline vitamin D level with the virological response of tenofovir treatment on chronic hepatitis B patients

LI Xuan, ZHANG Li-na, WANG Song, WANG Fang, NIE Guang, HE Qing

Department of liver diseases, The Third People’s Hospital of Shenzhen, Guangdong 518100, China

Received:2020-11-10 Online:2021-06-30 Published:2021-07-19
Contact: HE Qing,Email:heqingjoe@163.com

摘要/Abstract

摘要： 目的探索维生素D水平对替诺福韦治疗慢性乙型肝炎24周病毒学应答的影响。方法纳入2017年11月至2019年11月期间深圳市第三人民医院肝病医学中心收治的患者共115例,收集基线临床资料,包括人口学信息、病毒学指标、血常规、肝功能、凝血功能以及维生素D水平,根据治疗24周乙肝病毒定量结果分为阳性组和阴性组,通过单因素及多因素Logistic分析得出维生素D与病毒学应答的关系,将性别、HBeAg状态、HBV DNA水平作为分层因素进行亚组分析。结果 HBV DNA阳性组基线25(OH)D水平明显低于HBV DNA阴性组(P=0.002),多因素分析显示,24周HBV DNA转阴率OR值随着25(OH)D水平逐渐增加,亚组分析中,24周HBV DNA转阴率OR值均随着25(OH)D水平的升高而增加。结论 25(OH)D水平是影响替诺福韦治疗慢性乙型肝炎24周病毒学应答的独立影响因素。

关键词: 25羟维生素D, 替诺福韦, 病毒学应答, 慢性乙型肝炎

Abstract: Objective To investigate the association of baseline serum vitamin D level with the 24-week virological response of tenofovir treatment on chronic hepatitis B patients.Methods A total of 115 patients who were hospitalized in the department of liver diseases of the third people’s hospital of Shenzhen from November 2017 to November 2019, and met the inclusion criteria were enrolled in this study. Baseline clinical data were collected including demographic information, virological indicators, blood routines, Liver function, blood coagulation function and serum vitamin D level. According to the quantitative results of hepatitis B viral load at 24 weeks of treatment, the patients were divided into positive and negative groups. The relationship between vitamin D level and virological response was analyzed by logistic multivariate analysis. Gender, HBeAg status and HBV DNA level were used as the stratified factors.Results The baseline serum 25(OH)D level of the positive group was significantly lower than that of the negative group (P=0.002). Multivariate analysis showed that the 24-week HBV DNA negative conversion rate gradually increased with an increase of baseline 25 (OH)D level. In the subgroup analysis, the 24-week HBV DNA negative conversion rate all increased with the increase of baseline 25 (OH)D level.Conclusion The level of 25(OH)D is an independent factor associated with the 24-week virological response of tenofovir treatment on chronic hepatitis B patients.

Key words: 25(OH)D level, Tenofovir disoproxil fumarate, Virological response, Chronic hepatitis B

李轩, 张丽娜, 王松, 王方, 聂广, 何清. 基线维生素D水平对替诺福韦治疗慢性乙型肝炎疗效的影响[J]. 肝脏, 2021, 26(6): 621-624.

LI Xuan, ZHANG Li-na, WANG Song, WANG Fang, NIE Guang, HE Qing. The association of baseline vitamin D level with the virological response of tenofovir treatment on chronic hepatitis B patients[J]. Chinese Hepatolgy, 2021, 26(6): 621-624.

参考文献

[1] WHO. Guidlines for the prevention,care and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization, 2015.
[2] Kim HJ, Cho JY, Kim YJ, et al. Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients. Korean J Intern Med, 2015,30:32-41.
[3] Martens PJ, Gysemans C, Verstuyf A, et al. Vitamin D's Effect on Immune Function. Nutrients, 2020,12:1248.
[4] 王贵强, 段钟平, 王福生, 等. 慢性乙型肝炎防治指南(2019年版). 实用肝脏病杂志, 2020,23:S9-S32.
[5] Terrault NA, Lok A, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology, 2018,67:1560-1599.
[6] Zeuzem S, Gane E, Liaw Y F, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol, 2009,51:11-20.
[7] Aziz M, Aziz H, Waheed Y, et al. Predictors of Therapeutic Outcome to Nucleotide Reverse Transcriptase Inhibitor in Hepatitis B Patients. Viral Immunol, 2018,31:632-638.
[8] Chen EQ, Bai L, Zhou TY, et al. Sustained suppression of viral replication in improving vitamin D serum concentrations in patients with chronic hepatitis B. Sci Rep, 2015,5:15441.
[9] Yu R, Tan D, Ning Q, et al. Association of baseline vitamin D level with genetic determinants and virologic response in patients with chronic hepatitis B. Hepatol Res, 2018,48:E213-E221.
[10] Guidotti LG, Isogawa M, Chisari FV. Host-virus interactions in hepatitis B virus infection. Curr Opin Immunol, 2015,36:61-66.
[11] Sintzel MB, Rametta M, Reder AT. Vitamin D and Multiple Sclerosis: A Comprehensive Review. Neurol Ther, 2018,7:59-85.
[12] He LJ, Zhang HP, Li HJ, et al. Effect of Serum Vitamin D Levels on Cellular Immunity and Antiviral Effects in Chronic Hepatitis B Patients. Clin Lab, 2016,62:1933-1939.
[13] 李冰, 黄辉红, 江自成, 等. 血清维生素D水平对慢性乙型肝炎患者抗病毒疗效的影响. 肝脏, 2018,23:895-897.
[14] Gal-Tanamy M, Bachmetov L, Ravid A, et al. Vitamin D: an innate antiviral agent suppressing hepatitis C virus in human hepatocytes. Hepatology, 2011,54:1570-1579.
[15] Matsumura T, Kato T, Sugiyama N, et al. 25-Hydroxyvitamin D3 suppresses hepatitis C virus production. Hepatology, 2012,56:1231-1239.